Samaritan Pharmaceuticals granted IND from FDA for HIV drug

NewsGuard 100/100 Score

Samaritan Pharmaceuticals has announced that it has filed an IND (Investigational New Drug) application for SP-6310 in the treatment of HIV-infected patients with abnormal cortisol levels.

Following discussions and protocol agreement with U.S. Food and Drug Administration (FDA), Samaritan will conduct an 8-week Phase II clinical study with SP-6310 in HIV-infected patients with abnormal cortisol levels while on antiretroviral therapy. Samaritan expects that the results of this study will confirm the positive results found in a previously conducted Phase I/II.

It has been hypothesized that HIV-associated disregulation of cortisol may play a role in the pathophysiology of AIDS, including modulation of cell-mediated immunity. Experimental evidence suggests that cortisol and its receptors are critically involved at some level in the regulation of immune function in HIV infection. Abnormal levels of cortisol and DHEA (Dehydroepiandrosterone) may switch the predominant immune response to HIV from TH1 to TH2 type responses and may be immunosuppressive as well. Therefore, treatment with a cortisol-modulating agent may improve immune function as well as quality of life in HIV-infected patients. Clinical study data shows that SP-6310, given orally, modulates cortisol levels in HIV-infected patients and, therefore, represents a potential therapy for the normalization of both low and high urinary cortisol levels in HIV-infected patients while on antiretroviral therapy.

Dr. Janet Greeson, Chief Executive Officer of Samaritan commented, “SP-6310 was born out of Samaritan’s intrinsic desire to bring significantly beneficial, affordable, first- and second-line treatment regimens to all suffering HIV patients, including those in the developing world. We believe SP-6310 has robust promise to do so.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New drug candidates show promise to reverse HIV immune evasion